197 results on '"Stefania Napolitano"'
Search Results
52. Data from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
- Author
-
Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini
- Abstract
The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resistance. We evaluated EPHA2 as a potential resistance marker to the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in colorectal cancer. We studied activation of EPHA2 in a panel of human colorectal cancer cell lines sensitive or resistant to anti-EGFR drugs. The in vitro and in vivo effects of ALW-II-41-27 (an EPHA2 inhibitor) and/or cetuximab treatment were tested. Formalin-fixed paraffin-embedded tumor specimens from 82 RAS wild-type (WT) metastatic colorectal cancer patients treated with FOLFIRI + cetuximab as first-line therapy in the CAPRI-GOIM trial were assessed for EPHA2 expression by immunohistochemistry and correlated with treatment efficacy. EPHA2 was differentially activated in colorectal cancer cell lines. Combined treatment with ALW-II-41-27 plus cetuximab reverted primary and acquired resistance to cetuximab, causing cell growth inhibition, inducing apoptosis and cell-cycle G1–G2 arrest. In tumor xenograft models, upon progression to cetuximab, ALW-II-41-27 addition significantly inhibited tumor growth. EPHA2 protein expression was detected in 55 of 82 tumor samples, frequently expressed in less-differentiated and left-sided tumors. High levels of EPHA2 significantly correlated with worse progression-free survival [8.6 months; confidence interval (CI) 95%, 6.4–10.8; vs. 12.3 months; CI 95%, 10.4–14.2; P = 0.03] and with increased progression rate (29% vs. 9%, P = 0.02). A specific EPHA2 inhibitor reverts in vitro and in vivo primary and acquired resistance to anti-EGFR therapy. EPHA2 levels are significantly associated with worse outcome in patients treated with FOLFIRI + cetuximab. These results highlight EPHA2 as a potential therapeutic target in metastatic colorectal cancer.
- Published
- 2023
53. Supplementary Figure 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
- Author
-
Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini
- Abstract
Supplementary Figure 1. A: Phosphoarray analysis of SW48 and SW48-CR cell lines. B: Silencing of EPHA2 decreases the sensitivity to ALW-II-41-27 in HCT15 and SW48-CR cell lines.
- Published
- 2023
54. Supplementary Figure 2 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
- Author
-
Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini
- Abstract
Supplementary Figure 2. A-B: Synergistic anti-proliferative effects of the combination of ALW-II-41-27 and cetuximab.C: Effect of Epha2 gene knockdown on cetuximab sensitivity in HCT116 and LOVO cell lines. D: Effects of combination treatment with ALW-II-41-27 and cetuximab on induction of apoptosis. E: Cell cycle distribution for HCT15 and SW48-CR following treatment with ALW-II-41-27 and/or cetuximab for 24, 48 and 72 hrs at indicated doses. F: Effects of EPHA2 blockade alone and in combination with cetuximab on intracellular signalling pathways of cell proliferation and survival.
- Published
- 2023
55. Supplementary Materials and Methods from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
- Author
-
Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini
- Abstract
Supplementary materials and methods
- Published
- 2023
56. Supplementary Table 2 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
- Author
-
Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini
- Abstract
Supplementary Table 2: EPHA2 expression in tumor samples of 82 RAS WT colorectal cancer patients from the GOIM-CAPRI trial
- Published
- 2023
57. Supplementary Table 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
- Author
-
Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini
- Abstract
Supplementary Table 1: Treatment with ALW-II-41-27 or cetuximab as single agents
- Published
- 2023
58. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival
- Author
-
Davide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, Lucia Esposito, Filippo Pietrantonio, Antonio Avallone, Evaristo Maiello, Chiara Cremolini, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini, Ciardiello, Davide, Famiglietti, Vincenzo, Napolitano, Stefania, Esposito, Lucia, Pietrantonio, Filippo, Avallone, Antonio, Maiello, Evaristo, Cremolini, Chiara, Troiani, Teresa, Martinelli, Erika, Ciardiello, Fortunato, and Martini, Giulia
- Subjects
Proto-Oncogene Proteins B-raf ,Neutrophils ,Rectal Neoplasms ,fungi ,anti-EGFR drug ,Gastroenterology ,Cetuximab ,colorectal cancer ,Antibodies, Monoclonal, Humanized ,Circulating Tumor DNA ,Oncology ,NLR ,Antineoplastic Combined Chemotherapy Protocols ,Colonic Neoplasms ,Humans ,Lymphocytes ,immunotherapy ,rechallenge treatment ,Colorectal Neoplasms - Abstract
Background: High neutrophil-to-lymphocyte ratio (NLR) is a poor prognostic factor in metastatic colorectal cancer (mCRC). Here we provide final results of CAVE mCRC trial, of cetuximab plus avelumab rechallenge in chemo-refractory mCRC patients and investigated the predictive role of NLR. Methods: All the 77 patients enrolled were included in the analysis. A cut-off of 3 was used to correlate baseline NLR with with overall survival (OS) and with progression free survival (PFS), in intention to treat (ITT) and in circulating tumor DNA (ctDNA) RAS/BRAF Wild Type (WT) patients. Results: In ITT population, NLR
- Published
- 2022
59. Supplementary Figure Legends from Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
- Author
-
Erika Martinelli, Fortunato Ciardiello, Davide Ciardiello, Anna Nappi, Vincenzo Sforza, Anna Capasso, Floriana Morgillo, Donata Vitagliano, Stefania Napolitano, and Teresa Troiani
- Abstract
PDF file - 116KB
- Published
- 2023
60. supplementary figure 1 from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
- Author
-
Teresa Troiani, Fortunato Ciardiello, Francesco Merolla, Raffaele De Palma, Giusy Barra, Floriana Morgillo, Donata Vitagliano, Liberato Berrino, Maria Donniacuo, Erika Martinelli, Barbara Rinaldi, Giulia Martini, and Stefania Napolitano
- Abstract
supplementary figure 1. Effects of cetuximab in combination with regorafenib in a panel of CRC cell lines with primary and acquired resistance to anti-EGFR inhibitor in vitro.
- Published
- 2023
61. Supplementary Table 2 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
- Author
-
Fortunato Ciardiello, Roberto Bianco, Liberato Berrino, Elena D'Aiuto, Raffaele De Palma, Anna Nappi, Vincenzo Sforza, Anna Capasso, Floriana Morgillo, Sara Costantino, Loreta Pia Ciuffreda, Donata Vitagliano, Stefania Napolitano, Erika Martinelli, and Teresa Troiani
- Abstract
PDF file 145K, genes down regulated in GEO-CR versus GEO
- Published
- 2023
62. Supplementary Figure Legend from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
- Author
-
Fortunato Ciardiello, Roberto Bianco, Liberato Berrino, Elena D'Aiuto, Raffaele De Palma, Anna Nappi, Vincenzo Sforza, Anna Capasso, Floriana Morgillo, Sara Costantino, Loreta Pia Ciuffreda, Donata Vitagliano, Stefania Napolitano, Erika Martinelli, and Teresa Troiani
- Abstract
PDF file 84K, Supplementary figure legend
- Published
- 2023
63. Supplementary Figures 1 - 3, Tables 1 - 3 from Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
- Author
-
Erika Martinelli, Fortunato Ciardiello, Davide Ciardiello, Anna Nappi, Vincenzo Sforza, Anna Capasso, Floriana Morgillo, Donata Vitagliano, Stefania Napolitano, and Teresa Troiani
- Abstract
PDF file - 1325KB, Caption Supplementary Figure 1 A and 1B. The combined treatment of cetuximab and the selective MEK1/2 inhibitor BAY 86-9766 induce a synergistic growth inhibitory effects in CRC cell lines with primary and acquired resistance to cetuximab and an antagonistic effects in cetuximab-sensitive CRC cell lines. Caption Supplementary Figure 2. The BAY 86-9766 treatment, in CRC cancer cell lines with primary and acquired resistance to cetuximab, induce a dose dependent reduction of MAPK and MEK phosphorylation. Caption Supplementary Figure 3. The combined treatment of cetuximab and the selective MEK1/2 inhibitor BAY 86-9766 was well tolerated by mice, with no weight loss or other signs of acute or delayed toxicity. Caption Supplementary Table 1A and 1B. The panel of CRC cell lines have been treated with several concentrations of cetuximab and selective MEK1/2 inhibitors (BAY 86-9766, Selumetinib and Pimasertib), showing differential sensitivity to the drugs. Caption Supplementary Table 2. We have performed the experiments on a panel of eight human CRC cell lines having different mutation profiles in KRAS, NRAS, BRAF, PIK3CA and EGFR genes. Caption Supplementary Table 3. In the CRC cell lines with acquired and primary resistance to cetuximab, the treatment with the selective MEK1/2 inhibitor BAY 86-9766 determined synergistic growth inhibitory effects in combination with cetuximab.
- Published
- 2023
64. Data from Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
- Author
-
Erika Martinelli, Fortunato Ciardiello, Davide Ciardiello, Anna Nappi, Vincenzo Sforza, Anna Capasso, Floriana Morgillo, Donata Vitagliano, Stefania Napolitano, and Teresa Troiani
- Abstract
Purpose: The EGFR-independent activation of the RAS/RAF/MEK/MAPK pathway is one of the resistance mechanisms to cetuximab.Experimental Design: We have evaluated, in vitro and in vivo, the effects of BAY 86-9766, a selective MEK1/2 inhibitor, in a panel of human colorectal cancer cell lines with primary or acquired resistance to cetuximab.Results: Among the colorectal cancer cell lines, five with a KRAS mutation (LOVO, HCT116, HCT15, SW620, and SW480) and one with a BRAF mutation (HT29) were resistant to the antiproliferative effects of cetuximab, whereas two cells (GEO and SW48) were highly sensitive. Treatment with BAY 86-9766 determined dose-dependent growth inhibition in all cancer cells, including two human colorectal cancer cells with acquired resistance to cetuximab (GEO-CR and SW48-CR), with the exception of HCT15 cells. Combined treatment with cetuximab and BAY 86-9766 induced a synergistic antiproliferative and apoptotic effects with blockade in the MAPK and AKT pathway in cells with either primary or acquired resistance to cetuximab. The synergistic antiproliferative effects were confirmed using other two selective MEK1/2 inhibitors, selumetinib and pimasertib, in combination with cetuximab. Moreover, inhibition of MEK expression by siRNA restored cetuximab sensitivity in resistant cells. In nude mice bearing established human HCT15, HCT116, SW48-CR, and GEO-CR xenografts, the combined treatment with cetuximab and BAY 86-9766 caused significant tumor growth inhibition and increased mice survival.Conclusion: These results suggest that activation of MEK is involved in both primary and acquired resistance to cetuximab and the inhibition of EGFR and MEK could be a strategy for overcoming anti-EGFR resistance in patients with colorectal cancer. Clin Cancer Res; 20(14); 3775–86. ©2014 AACR.
- Published
- 2023
65. Data from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
- Author
-
Fortunato Ciardiello, Roberto Bianco, Liberato Berrino, Elena D'Aiuto, Raffaele De Palma, Anna Nappi, Vincenzo Sforza, Anna Capasso, Floriana Morgillo, Sara Costantino, Loreta Pia Ciuffreda, Donata Vitagliano, Stefania Napolitano, Erika Martinelli, and Teresa Troiani
- Abstract
Purpose: Although cetuximab, an anti-EGF receptor (EGFR) monoclonal antibody, is an effective treatment for patients with KRAS wild-type metastatic colorectal cancer (mCRC), its clinical use is limited by onset of resistance.Experimental Design: We characterized two colorectal cancer models to study the mechanisms of acquired resistance to cetuximab.Results: Following chronic treatment of nude mice bearing cetuximab-sensitive human GEO colon xenografts, cetuximab-resistant GEO (GEO-CR) cells were obtained. In GEO-CR cells, proliferation and survival signals were constitutively active despite EGFR inhibition by cetuximab treatment. Whole gene expression profiling identified a series of genes involved in the hepatocyte growth factor (HGF)-MET–dependent pathways, which were upregulated in GEO-CR cells. Furthermore, activated, phosphorylated MET was detected in GEO-CR cells. A second colorectal cancer cell line with acquired resistance to cetuximab was obtained (SW48-CR). Inhibition of MET expression by siRNA restored cetuximab sensitivity in GEO-CR and SW48-CR cells, whereas exogenous activation of MET by HGF stimulation in cetuximab-sensitive GEO and SW48 cells induced resistance to cetuximab. Treatment of GEO-CR and SW48-CR cells with PHA665752, a selective MET inhibitor, inhibited cell growth, proliferation, and survival signals and impaired cancer cell migration. Overexpression of TGF-α, a specific EGFR ligand, was involved in the acquisition of cetuximab resistance in GEO-CR and SW48-CR cells. In fact, TGF-α overexpression induced the EGFR–MET interaction, with subsequent MET phosphorylation and activation of MET downstream effectors in GEO-CR and SW48-CR cells.Conclusions: These results suggest that overexpression of TGF-α through induction of EGFR–MET interaction contributes to cetuximab resistance in colorectal cancer cells. The combined inhibition of EGFR and MET receptor could represent a strategy for preventing and/or overcoming cetuximab resistance in patients with colorectal cancer. Clin Cancer Res; 19(24); 6751–65. ©2013 AACR.
- Published
- 2023
66. supplementary table 1 from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
- Author
-
Teresa Troiani, Fortunato Ciardiello, Francesco Merolla, Raffaele De Palma, Giusy Barra, Floriana Morgillo, Donata Vitagliano, Liberato Berrino, Maria Donniacuo, Erika Martinelli, Barbara Rinaldi, Giulia Martini, and Stefania Napolitano
- Abstract
supplementary table 1. mutational status
- Published
- 2023
67. supplementary figure 3 from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
- Author
-
Teresa Troiani, Fortunato Ciardiello, Francesco Merolla, Raffaele De Palma, Giusy Barra, Floriana Morgillo, Donata Vitagliano, Liberato Berrino, Maria Donniacuo, Erika Martinelli, Barbara Rinaldi, Giulia Martini, and Stefania Napolitano
- Abstract
supplementary figure 3. Pro-apoptotic effects of cetuximab in combination with regorafenib in SW620 CRC cell line with primary resistance to anti-EGFR inhibitor.
- Published
- 2023
68. Supplementary Figure 2 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
- Author
-
Fortunato Ciardiello, Roberto Bianco, Liberato Berrino, Elena D'Aiuto, Raffaele De Palma, Anna Nappi, Vincenzo Sforza, Anna Capasso, Floriana Morgillo, Sara Costantino, Loreta Pia Ciuffreda, Donata Vitagliano, Stefania Napolitano, Erika Martinelli, and Teresa Troiani
- Abstract
PDF file 1516K, Inhibition of MET expression restores cetuximab sensitivity in SW48-CR cells
- Published
- 2023
69. Supplementary Table 1 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
- Author
-
Fortunato Ciardiello, Roberto Bianco, Liberato Berrino, Elena D'Aiuto, Raffaele De Palma, Anna Nappi, Vincenzo Sforza, Anna Capasso, Floriana Morgillo, Sara Costantino, Loreta Pia Ciuffreda, Donata Vitagliano, Stefania Napolitano, Erika Martinelli, and Teresa Troiani
- Abstract
PDF file 184K, genes up regulated in GEO-CR versus GEO
- Published
- 2023
70. Supplementary Figure 1 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
- Author
-
Fortunato Ciardiello, Roberto Bianco, Liberato Berrino, Elena D'Aiuto, Raffaele De Palma, Anna Nappi, Vincenzo Sforza, Anna Capasso, Floriana Morgillo, Sara Costantino, Loreta Pia Ciuffreda, Donata Vitagliano, Stefania Napolitano, Erika Martinelli, and Teresa Troiani
- Abstract
PDF file 1732K, Development and characterization of cetuximab-resistant SW48 (SW48-CR) colon cancer cells
- Published
- 2023
71. supplementary figure legend from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
- Author
-
Teresa Troiani, Fortunato Ciardiello, Francesco Merolla, Raffaele De Palma, Giusy Barra, Floriana Morgillo, Donata Vitagliano, Liberato Berrino, Maria Donniacuo, Erika Martinelli, Barbara Rinaldi, Giulia Martini, and Stefania Napolitano
- Abstract
supplementary figure legend
- Published
- 2023
72. supplementary figure 4 from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
- Author
-
Teresa Troiani, Fortunato Ciardiello, Francesco Merolla, Raffaele De Palma, Giusy Barra, Floriana Morgillo, Donata Vitagliano, Liberato Berrino, Maria Donniacuo, Erika Martinelli, Barbara Rinaldi, Giulia Martini, and Stefania Napolitano
- Abstract
supplementary figure 4. Effects of cetuximab in combination with regorafenib on mice body weight.
- Published
- 2023
73. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy
- Author
-
Christine M. Parseghian, Ryan Sun, Melanie Woods, Stefania Napolitano, Hey Min Lee, Jumanah Alshenaifi, Jason Willis, Shakayla Nunez, Kanwal P. Raghav, Van K. Morris, John P. Shen, Madhulika Eluri, Alexey Sorokin, Preeti Kanikarla, Eduardo Vilar, Marko Rehn, Agnes Ang, Teresa Troiani, Scott Kopetz, Parseghian, Christine M, Sun, Ryan, Woods, Melanie, Napolitano, Stefania, Lee, Hey Min, Alshenaifi, Jumanah, Willis, Jason, Nunez, Shakayla, Raghav, Kanwal P, Morris, Van K, Shen, John P, Eluri, Madhulika, Sorokin, Alexey, Kanikarla, Preeti, Vilar, Eduardo, Rehn, Marko, Ang, Agne, Troiani, Teresa, and Kopetz, Scott
- Subjects
Cancer Research ,Oncology - Abstract
PURPOSE Acquired resistance to anti–epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in KRAS/NRAS/EGFR, among other MAPK-pathway members. However, this was primarily on the basis of single-agent EGFRi trials and little is known about the resistance mechanisms of EGFRi combined with effective cytotoxic chemotherapy in previously untreated patients. METHODS We analyzed paired plasma samples from patients with RAS/BRAF/EGFR wild-type metastatic CRC enrolled in three large randomized trials evaluating EGFRi in the first line in combination with chemotherapy and as a single agent in third line. The mutational signature of the alterations acquired with therapy was evaluated. CRC cell lines with resistance to cetuximab, infusional fluorouracil, leucovorin, and oxaliplatin, and SN38 were developed, and transcriptional changes profiled. RESULTS Patients whose tumors were treated with and responded to EGFRi alone were more likely to develop acquired mutations (46%) compared with those treated in combination with cytotoxic chemotherapy (9%). Furthermore, contrary to the generally accepted hypothesis of the clonal evolution of acquired resistance, we demonstrate that baseline resistant subclonal mutations rarely expanded to become clonal at progression, and most remained subclonal or disappeared. Consistent with this clinical finding, preclinical models with acquired resistance to either cetuximab or chemotherapy were cross-resistant to the alternate agents, with transcriptomic profiles consistent with epithelial-to-mesenchymal transition. By contrast, commonly acquired resistance alterations in the MAPK pathway do not affect sensitivity to cytotoxic chemotherapy. CONCLUSION These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.
- Published
- 2023
74. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions
- Author
-
Vincenzo De Falco, Gabriella Suarato, Rossella Napolitano, Giuseppe Argenziano, Vincenzo Famiglietti, Annarita Amato, Alberto Servetto, Roberto Bianco, Luigi Formisano, Vincenzo Terrano, Alfonso Esposito, Maria Cristina Giugliano, Davide Ciardiello, Fortunato Ciardiello, Stefania Napolitano, Teresa Troiani, De Falco, V., Suarato, G., Napolitano, R., Argenziano, G., Famiglietti, V., Amato, A., Servetto, A., Bianco, R., Formisano, L., Terrano, V., Esposito, A., Giugliano, M. C., Ciardiello, D., Ciardiello, F., Napolitano, S., Troiani, T., De Falco, Vincenzo, Suarato, Gabriella, Napolitano, Rossella, Argenziano, Giuseppe, Famiglietti, Vincenzo, Amato, Annarita, Servetto, Alberto, Bianco, Roberto, Formisano, Luigi, Terrano, Vincenzo, Esposito, Alfonso, Giugliano, Maria Cristina, Ciardiello, Davide, Ciardiello, Fortunato, Napolitano, Stefania, and Troiani, Teresa
- Subjects
Cancer Research ,Oncology ,real-world data ,melanoma ,adjuvant therapy ,immunotherapy ,targeted therapy - Abstract
Adjuvant immunotherapy (IO) and targeted therapy (TT) have improved relapse-free survival (RFS) in patients with stage III melanoma, although about 25% of them relapse within a year. However, real-world data on treatment efficacy and safety as well as management of treatment recurrences are still limited. We retrospectively analyzed 113 patients with stage III melanoma who received at least one cycle of anti-PD-1 (nivolumab or pembrolizumab) or dabrafenib + trametinib as adjuvant therapy. Most of patients included into the analyses harbor BRAV600E mutation (66.4%) and had a stage IIIC melanoma (63.7%). Immunotherapy was administered in 48.7% of patients, whereas targeted therapy in 51.3% At data cut-off, median RFS was not reached with 12- and 24-months RFS of 81% and 64%, respectively. No new adverse events were registered. Thirty patients (26.5%) relapsed, mainly at distant sites. Patient treated with IO recurred mostly during adjuvant treatment (ON-treatment) while patients treated with TT relapsed at the end of treatment (OFF-treatment). At relapse, surgery, radiotherapy and systemic therapy were used alone or in combination. Among patients who started a first-line therapy, an excellent response switching to a different treatment was observed. Real-world outcomes and safety of adjuvant treatment for resected stage III melanoma appear comparable to clinical trials data. Moreover, management of recurrences depends on type of relapse (loco-regional vs distant) and timing (during vs OFF treatment). Furthermore, patients who relapse after adjuvant TT respond well to subsequent anti-PD1 based therapy.
- Published
- 2023
75. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in
- Author
-
Christine M, Parseghian, Ryan, Sun, Melanie, Woods, Stefania, Napolitano, Hey Min, Lee, Jumanah, Alshenaifi, Jason, Willis, Shakayla, Nunez, Kanwal P, Raghav, Van K, Morris, John P, Shen, Madhulika, Eluri, Alexey, Sorokin, Preeti, Kanikarla, Eduardo, Vilar, Marko, Rehn, Agnes, Ang, Teresa, Troiani, and Scott, Kopetz
- Abstract
Acquired resistance to anti-epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations inWe analyzed paired plasma samples from patients withPatients whose tumors were treated with and responded to EGFRi alone were more likely to develop acquired mutations (46%) compared with those treated in combination with cytotoxic chemotherapy (9%). Furthermore, contrary to the generally accepted hypothesis of the clonal evolution of acquired resistance, we demonstrate that baseline resistant subclonal mutations rarely expanded to become clonal at progression, and most remained subclonal or disappeared. Consistent with this clinical finding, preclinical models with acquired resistance to either cetuximab or chemotherapy were cross-resistant to the alternate agents, with transcriptomic profiles consistent with epithelial-to-mesenchymal transition. By contrast, commonly acquired resistance alterations in the MAPK pathway do not affect sensitivity to cytotoxic chemotherapy.These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.
- Published
- 2022
76. Panitumumab plus trifluridine/tipiracil as anti-Epidermal Growth Factor Receptor rechallenge therapy in chemo-refractory RAS wild-type metastatic colorectal cancer: the randomized phase 2 VELO trial
- Author
-
Fortunato Ciardiello, Teresa Troiani, Stefania Napolitano, Vincenzo De Falco, Giulia Martini, Davide Ciardiello, Erika Martinelli, Carminia Maria Della Corte, Lucia Esposito, Vincenzo Famiglietti, Alessandra Di Liello, Antonio Avallone, Claudia Cardone, Alfonso De Stefano, Vincenzo Montesarchio, Maria Giulia Zampino, Roberto Bordonaro, Mario Scartozzi, Daniele Santini, Massimo Di Maio, Ferdinando De Vita, Lucia Altucci, and Francesca Marrone
- Abstract
Current therapies for chemo-refractory metastatic colorectal cancer (mCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors in RAS wild-type (WT) mCRC could be valuable in this setting. In VELO, a randomized two-arm phase 2 trial, anti-EGFR monoclonal antibody panitumumab plus standard-of-care trifluridine/tipiracil (31 patients, arm B) was compared to trifluridine/tipiracil (31 patients, arm A) as third-line therapy (ClinicalTrials.gov Identifier NCT05468892). Primary endpoint, progression-free survival (PFS), was met. Median PFS was 4.0 months in arm B versus 2.5 months in arm A [hazard ratio (HR): 0.48; 95% CI 0.28–0.82; P = 0.007]. Baseline plasma RAS/BRAF WT circulating tumor DNA identified patients obtaining prolonged clinical benefit with panitumumab plus trifluridine/tipiracil as compared to trifluridine/tipiracil with PFS rates at 6 months of 38.5% versus 13% and at 12 months of 15.4% versus 0%, respectively. These findings warrant further development for liquid biopsy-guided anti-EGFR rechallenge combination strategies in chemo-refractory RAS WT mCRC.
- Published
- 2022
77. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
- Author
-
Gianluca Arrichiello, Alessandra Perrone, Stefania Napolitano, Giulia Martini, Vincenzo De Falco, Pasquale Incoronato, Maria Maddalena Laterza, Gaetano Facchini, Vincenzo Famiglietti, Valeria Nacca, Fernando Paragliola, Rossella Napolitano, Gabriella Suarato, Antonella Nicastro, Erika Martinelli, Davide Ciardiello, Fortunato Ciardiello, Teresa Troiani, Arrichiello, Gianluca, Perrone, Alessandra, Napolitano, Stefania, Martini, Giulia, De Falco, Vincenzo, Incoronato, Pasquale, Laterza, Maria Maddalena, Facchini, Gaetano, Famiglietti, Vincenzo, Nacca, Valeria, Paragliola, Fernando, Napolitano, Rossella, Suarato, Gabriella, Nicastro, Antonella, Martinelli, Erika, Ciardiello, Davide, Ciardiello, Fortunato, and Troiani, Teresa
- Subjects
Male ,Adult ,Aged, 80 and over ,Cancer Research ,Antineoplastic Combined Chemotherapy Protocol ,Colorectal Neoplasm ,Middle Aged ,Trifluridine ,Bevacizumab ,Oncology ,Retrospective Studie ,Colonic Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Pharmacology (medical) ,Female ,Uracil ,Colorectal Neoplasms ,Human ,Aged ,Retrospective Studies - Abstract
Background The combination of trifluridine-tipiracil and bevacizumab was compared with trifluridine-tipiracil monotherapy in a randomized, open-label, phase II trial, resulting in a statistically significant and clinically relevant improvement in progression-free survival (PFS), with tolerable toxicity in patients with refractory metastatic colorectal cancer (mCRC); however, evidence supporting the role of this combination in a real-world setting is limited. Objective The aim of our work was to provide further evidence on the activity and safety of this combination in a real-world series of Western mCRC patients refractory or intolerant to previous therapies. Patient and Methods We conducted a retrospective, observational study of patients with mCRC refractory or intolerant to standard therapies. Patients were treated with trifluridine-tipiracil and bevacizumab. Previous therapy with fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab, aflibercept, regorafenib, and cetuximab or panitumumab (only RAS wild-type) was allowed, as was previous participation in clinical trials. Clinicopathological characteristics, overall response rate (ORR), disease control rate (DCR), overall survival (OS), PFS, and safety data were retrospectively collected and analyzed. Results We recorded 31 patients treated between 1 December 2017 and 30 June 2022. Median age was 69 years (range 38-82 years), 39% were male, 100% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1, tumor location was left-sided in 77% of cases, 54% had synchronous presentation, 35% were RAS mutant, 3% were BRAF mutant, and 71% underwent primary tumor resection; 64% of patients had liver metastases, 55% had lung metastases, and 23% had peritoneal carcinomatosis. The median number of previous treatment lines was 2 (range 0-5), and 84% of patients received at least one previous anti-angiogenic agent. The ORR and DCR were 3% and 71%, respectively. With a median follow-up of 8 months (range 2-39), median PFS was 6 months (95% confidence interval [CI] 3.1-8.9 months) and median OS was 14 months (95% CI 10.1-17.8 months). Adverse events of any grade were reported in 58% of patients. The most common grade 3-4 toxicities were neutropenia (19%) and anemia (6%); 35% of patients required either dose delays or dose reductions due to toxicity. Granulocyte colony-stimulating factor (G-CSF) prophylaxis was administered either on first or subsequent cycles of treatment in 35% of patients. No treatment-related deaths occurred. Sixty percent of the patients who discontinued treatment eventually received one or more lines of subsequent therapy. Conclusions Our series provides further evidence on the activity and safety of the combination of trifluridine-tipiracil and bevacizumab in a real-world series of Western refractory mCRC patients.
- Published
- 2022
78. Clinical management of metastatic colorectal cancer in the era of precision medicine
- Author
-
Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Josep Tabernero, Andres Cervantes, Institut Català de la Salut, [Ciardiello F, Martini G, Napolitano S] Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. [Ciardiello D] Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Division of Medical Oncology, IRCCS Foundation Home for the Relief of Suffering, San Giovanni Rotondo, Italy. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institute of Oncology, University of Vic/Central University of Catalonia, Barcelona, Spain. Oncology Institute of BarcelonaQuironsalud, Biomedical Research Center in Cancer, Barcelona, Spain. [Cervantes A] Medical Oncology Department, Instituto de Investigación Sanitaria Valencia Biomedical Research Institute, University of Valencia, Valencia Spain. Carlos III Institute of Health, Biomedical Research Center in Cancer, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus, Ciardiello, Fortunato, Ciardiello, Davide, Martini, Giulia, Napolitano, Stefania, Tabernero, Josep, and Cervantes, Andres
- Subjects
Rectal Neoplasms ,metastatic colorectal cancer ,precision medicine ,tumor molecular profiling ,Hematology ,Other subheadings::/therapy [Other subheadings] ,Prognosis ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES] ,digestive system diseases ,Còlon - Càncer - Tractament ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES] ,Oncology ,terapéutica::medicina de precisión [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,molecular target therapy ,Colonic Neoplasms ,Recte - Càncer - Tractament ,Biomarkers, Tumor ,Tumor Microenvironment ,Humans ,immunotherapy ,Medicina personalitzada ,Colorectal Neoplasms ,Therapeutics::Precision Medicine [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Otros calificadores::/terapia [Otros calificadores] - Abstract
Immunotherapy; Metastatic colorectal cancer; Precision medicine Inmunoterapia; Cáncer colorrectal metastásico; Medicina de precisión Immunoteràpia; Càncer colorectal metastàtic; Medicina de precisió Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with localized disease eventually develop metastases. Appropriate clinical management of these patients is still a challenging medical issue. Major efforts have been made to unveil the molecular landscape of mCRC. This has resulted in the identification of several druggable tumor molecular targets with the aim of developing personalized treatments for each patient. This review summarizes the improvements in the clinical management of patients with mCRC in the emerging era of precision medicine. In fact, molecular stratification, on which the current treatment algorithm for mCRC is based, although it does not completely represent the complexity of this disease, has been the first significant step toward clinically informative genetic profiling for implementing more effective therapeutic approaches. This has resulted in a clinically relevant increase in mCRC disease control and patient survival. The next steps in the clinical management of mCRC will be to integrate the comprehensive knowledge of tumor gene alterations, of tumor and microenvironment gene and protein expression profiling, of host immune competence as well as the application of the resulting dynamic changes to a precision medicine-based continuum of care for each patient. This approach could result in the identification of individual prognostic and predictive parameters, which could help the clinician in choosing the most appropriate therapeutic program(s) throughout the entire disease journey for each patient with mCRC. Fortunato Ciardiello was supported by a grant from Regione Campania (I-Cure Research Project Cup 21C17000030007). Andres Cervantes was supported by grants from the Instituto de Salud Carlos III (PI18/01909 and PI21/00689). Fortunato Ciardiello reports institutional research grants from Amgen, Merck KGaA, Merck Sharp & Dohme, Pfizer, Pierre Fabre, Roche, and Servier; and service on advisory boards for Bayer, Merck KGaA, Merck Sharp & Dohme, Pierre Fabre, Roche, and Servier outside the submitted work. Davide Ciardiello reports a travel grant from Sanofi outside the submitted work. Stefania Napolitano reports honoraria from Bristol Myers Squibb and Novartis outside the submitted work. Josep Tabernero reports advisory board or scientific consultancy fees from Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Roche, Genentech, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck KGaA, Merus, Merck Sharp & Dohme, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, SotioBiotech, Taiho, Tessa Therapeutics, and TheraMyc outside the submitted work. Andres Cervantes reports institutional research grants from Genentech, Merck KGaA, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Takeda, and Fibrogen; and honoraria or speaker’s fees from Amgen, Merck KGaA, Roche, Bayer, Servier, and Pierre Fabre outside the submitted work. Giulia Martini reports no conflicts of interest.
- Published
- 2022
79. Abstract 77: Recapitulating metastatic colorectal cancer in somatic mutation models for investigating the tumor immune microenvironment in minimal residual disease
- Author
-
Alaa M. Mohamed, Melinda Soeung, Jumanah Alshenaifi, Natalie Fowlkes, Ganiraju Manyam, Jennifer Davis, Amanda Anderson, Will Norton, Angela K. Deem, Sisi Gao, Isha Khanduri, Christopher Bistow, Federica Carbone, Stefania Napolitano, Justin Huang, Dipen M. Maru, David G. Menter, Giulio F. Draetta, Giannicola Genovese, and Scott Kopetz
- Subjects
Cancer Research ,Oncology - Abstract
Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide. One major factor contributing to the high mortality rate of CRC is the presence of microscopic minimal residual disease (MRD) that remains radiographically undetectable and persist regardless of therapeutic interventions. In fact, many CRC patients who have received therapy with curative intent will experience recurrence years later due to MRD, which can progress to recurrent disease that results in clinical morbidity. While immune modulation is crucial for mediating progression and metastasis of primary CRC tumors, how micrometastases suppress or evade antitumor immunity and/or maintain a state of dormancy before growing into macrometastases remains poorly understood. Filling this knowledge gap requires establishing and utilizing models capable of accurately recapitulating the immune phenotype of human microsatellite stable (MSS) metastatic CRC. To this end, we generated genetically engineered, syngeneic mouse colonic organoids using CRE recombinase technology to recapitulate MSS metastatic CRC models with APC and TP53 mutations. After establishing hematologic experimental metastases, histopathological examination confirmed that those present in the liver bore a close resemblance to human colorectal adenocarcinoma liver metastases. We then leveraged our model to test the hypothesis that the activation of suppressive immune cell populations is key for enabling the establishment and progression of MRD. We performed high-plex immunofluorescent co-localization analysis to delineate the immune compartments of micro- and macrometastases. Our results showed that, overall, leukocytes (CD45+ cells) decreased as metastatic tumor foci in the liver progressed. Specifically, cytotoxic CD8+ T cell densities were markedly reduced as tumor metastases progressed to macroscopic disease. Furthermore, populations of CD4+FOXP3+ (T-reg) cells increased as tumors progressed, with an increase in the ratio of CD4+FOXP3+ to CD8+ cells during tumor progression. Additionally, M2 macrophage density (IBA-1+, CD163+) increased as the liver metastases progressed in size. Overall, our findings support our hypothesis, and initiate the first step for identifying suppressive immune infiltrates that may be exploited for therapeutic targeting. Importantly, our somatic mutation-based modeling strategy enables a highly precise recapitulation of the mutational drivers and heterogeneity that occurs in CRC patients as well as provides a valuable resource for research aimed at elucidating the immunobiology of MRD. Citation Format: Alaa M. Mohamed, Melinda Soeung, Jumanah Alshenaifi, Natalie Fowlkes, Ganiraju Manyam, Jennifer Davis, Amanda Anderson, Will Norton, Angela K. Deem, Sisi Gao, Isha Khanduri, Christopher Bistow, Federica Carbone, Stefania Napolitano, Justin Huang, Dipen M. Maru, David G. Menter, Giulio F. Draetta, Giannicola Genovese, Scott Kopetz. Recapitulating metastatic colorectal cancer in somatic mutation models for investigating the tumor immune microenvironment in minimal residual disease [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 77.
- Published
- 2023
80. Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial
- Author
-
Stefania Napolitano, Vincenzo De Falco, Giulia Martini, Lucia Esposito, Vincenzo Famiglietti, Erika Martinelli, Davide Ciardiello, Francesca Marrone, Antonio Avallone, Claudia Cardone, Alfonso De Stefano, Vincenzo Montesarchio, M. Giulia Zampino, Roberto Bordonaro, Mario Scartozzi, Daniele Santini, Massimo Di Maio, Fortunato Ciardiello, and Teresa Troiani
- Subjects
Cancer Research ,Oncology - Abstract
129 Background: Rechallenge therapy with epidermal growth factor receptor (EGFR) inhibitors in chemo-refractory metastatic colorectal cancer (mCRC) is an emerging therapeutic approach. Trifluridine-tipiracil is approved for treatment of chemo-refractory mCRC patients. Methods: Chemo-refractory RAS WT mCRC patients, that had a major response (partial or complete response) to first-line chemotherapy plus an anti-EGFR monoclonal antibody and had an-anti-EGFR drug-free interval during second-line therapy of four or more months were randomized in a phase II trial to assess the addition of the anti-EGFR monoclonal antibody panitumumab to trifluridine-tipiracil as third-line rechallenge therapy. The primary endpoint was progression free survival (PFS). Baseline plasma was analyzed for circulating free tumor (ct) DNA by using Biocartis Idylla platform to detect mutations in KRAS, NRAS, BRAF ( V600E) and EGFRextracellular domain ( S492R). In 24 patients with baseline RAS/BRAF wild type (WT) ctDNA, Foundation One liquid CDx (324 gene profiling) was also performed before treatment and at disease progression. Results: 62 patients were treated with trifluridine-tipiracil (31 patients, arm A) or with trifluridine-tipiracil plus panitumumab (31 patients, arm B). As of September 16, 2022, 1 patient in arm A and 2 patients in arm B were on treatment. The primary endpoint was met. Median PFS (mPFS) was 4 months in arm B versus 2.5 months in arm A [hazard ratio (HR): 0.48; 95% CI 0.28-0.82; P = 0.007]. Baseline plasma RAS/BRAF WT ctDNA was found in 23/31 patients in Arm A and in 26/31 patients in Arm B. In this group, mPFS was 4.5 months in Arm B versus 2.6 months in Arm A (HR: 0.48; 95% CI 0.26-0.89; P = 0.019). Disease control (major responses plus stable disease) was higher for patients in Arm B compared to Arm A (81% versus 48%), whereas disease progression was the best response in 19% versus 52% patients, respectively. PFS rates at 6 and 12 months were 38.5% and 15.4% in arm B versus 13% and 0% in arm A. At disease progression, Foundation One liquid CDx detected several mutations within the EGFR pathway, which could correlate with cancer cell resistance to panitumumab. Conclusions: This is the first prospective randomized trial which evaluated anti-EGFR monoclonal antibody (panitumumab) in addition to standard of care (trifluridine-tipiracil) as third-line rechallenge therapy in chemo-refractory RASWT mCRC patients. Baseline liquid biopsy allows selection of RAS/BRAF WT ctDNA patients who could have a relevant clinical benefit. Clinical trial information: NCT05468892 .
- Published
- 2023
81. La recherche conceptuelle en psychanalyse comme occasion de formation. Un cas italien
- Author
-
Riccardo Galiani and Stefania Napolitano
- Subjects
Psychiatry and Mental health ,Clinical Psychology - Abstract
Les auteurs soutiennent la pertinence de la presence de la psychanalyse dans la formation et la recherche universitaires. A partir de considerations a propos du rapport entre psychanalyse et universite que l’on retrouve dans la litterature psychanalytique et de quelques exemples d’enseignement academique de la psychanalyse, les auteurs exposent leur approche de la recherche en psychanalyse, le developpement d’une methode de recherche conceptuelle et les resultats d’un travail specifique. Une telle approche manifeste les potentialites de la recherche conceptuelle en psychanalyse, pas seulement par rapport a la valeur scientifique d’une telle recherche, mais aussi au niveau de la formation de pointe.
- Published
- 2020
82. Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients
- Author
-
Davide Ciardiello, Teresa Troiani, Erika Martinelli, N. Zanaletti, Stefania Napolitano, P. Vitale, Giusi Barra, Raffaele De Palma, Vincenzo De Falco, M. Terminiello, Floriana Morgillo, Emilio Francesco Giunta, Giuseppe Argenziano, Fortunato Ciardiello, Giunta, Emilio Francesco, Barra, Giusi, De Falco, Vincenzo, Argenziano, Giuseppe, Napolitano, Stefania, Vitale, Pasquale, Zanaletti, Nicoletta, Terminiello, Marinella, Martinelli, Erika, Morgillo, Floriana, Ciardiello, Davide, De Palma, Raffaele, Ciardiello, Fortunato, and Troiani, Teresa
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Skin Neoplasms ,Programmed Cell Death 1 Receptor ,lcsh:Medicine ,Cancer immunotherapy ,Peripheral blood mononuclear cell ,Article ,Tumour biomarkers ,Interferon-gamma ,Immune system ,Text mining ,Antineoplastic Agents, Immunological ,Internal medicine ,medicine ,Humans ,lcsh:Science ,Melanoma ,Advanced melanoma ,Aged ,Cancer ,Aged, 80 and over ,Multidisciplinary ,biology ,business.industry ,lcsh:R ,Middle Aged ,Prognosis ,Interleukin-10 ,Interleukin 10 ,Toxicity ,biology.protein ,Leukocytes, Mononuclear ,Biomarker (medicine) ,Tumour immunology ,Cytokines ,Female ,lcsh:Q ,Antibody ,business - Abstract
Anti-PD-1 antibodies revolutionized the treatment of advanced melanoma patients. However, one out of three do not respond to this therapy, with an overall poor prognosis. Identification of predictive biomarkers in patients receiving immune-based therapies is necessary for minimizing risk of toxicity and optimizing patient benefit and is still an important unmet clinical need. Recently, many studies have evaluated peripheral blood markers as potential biomarkers, but none so far have been validated. We collected at baseline peripheral blood samples from 18 consecutive advanced melanoma patients treated with anti-PD-1 therapy. Main pro- and anti-inflammatory cytokines were studied in PBMCs from baseline blood samples both evaluating mRNA expression by qRT-PCR and identifying PBMCs subpopulations by FACS analysis. We found that IFN-γ mRNA expression levels were significantly higher in responder patients compared to non-responder ones. Moreover, to better validate its role, we evaluated the IFN-γ/IL-10 ratio. This value was higher in responder patients. FACS analysis confirmed that CD4 + IFN-γ + PBMCs percentage was higher in responders. Our data suggest an interesting correlation between IFN-γ/IL-10 ratio and response to anti-PD-1 therapy in advanced melanoma patients, suggesting a new biomarker that could be easily incorporated in clinical practice.
- Published
- 2020
83. Enabling smart environment for monitoring cancer patients therapy through OncoSmart
- Author
-
Teresa Troiani, Stefania Napolitano, Marinella Terminiello, Pietro Paolo Vitiello, Fortunato Ciardiello, Erika Martinelli, Giuseppe Fenza, Francesco J. Orciuoli, and Luca Romanelli
- Abstract
Aim: Treatment-related health symptoms strongly compromise the success of therapy and the quality of life of cancer patients. Patient smart monitoring through wearable devices and the management of electronic patient-reported outcomes (ePROs) prevent missing symptomatic toxicities. This study describes a preliminary clinical trial adopting OncoSmart Software as a Medical Device in the Health Continuum Cancer Care Pathways, realized by Riatlas srl. Methods: The preliminary study enrolled eight mCRC (metastatic colorectal cancer) patients under active medical treatment between June 2019 and January 2020. OncoSmart provides a mobile app integrated with a smartwatch. The mobile app alerts patients to fill ePROs and integrates the smartwatch to collect vital parameters (blood pressure, heart rate, oxygen saturation, respiratory rate, pedometer, sleeping, etc.). On the physician side, OncoSmart provides an interactive dashboard for monitoring the patient’s therapy and treatment-related health symptoms. Results: Despite the low number of enrolled patients, the trial revealed interesting results about OncoSmart’s adoption, measured in compliance and concordance. Compliance is the participation of patients in self-reports, which was about 77%. Overall concordance between ePRO and symptoms detected by physicians at clinical visits was 80%. The remaining 20% included 15% of cases where ePROs included symptoms missed during the visit and 5% of cases where physicians reported toxicities not recorded by patients. Regarding the symptoms that led to treatment modifications and/or suspension, the concordance between PROs and the physician’s evaluation during the visit was 100%. Conclusion: New medical treatments aim at improving patients’ survival and quality of life; using solutions such as OncoSmart increases patient empowerment and engagement. The preliminary results of OncoSmart suggest pursuing further assessment of the impact of a PRO solution in routine clinical practice.
- Published
- 2022
84. Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
- Author
-
Giulia Martini, Davide Ciardiello, Marcello Dallio, Vincenzo Famiglietti, Lucia Esposito, Carminia Maria Della Corte, Stefania Napolitano, Morena Fasano, Antonietta Gerarda Gravina, Marco Romano, Carmelina Loguercio, Alessandro Federico, Evaristo Maiello, Concetta Tuccillo, Floriana Morgillo, Teresa Troiani, Massimo Di Maio, Erika Martinelli, Fortunato Ciardiello, Martini, Giulia, Ciardiello, Davide, Dallio, Marcello, Famiglietti, Vincenzo, Esposito, Lucia, Corte, Carminia Maria Della, Napolitano, Stefania, Fasano, Morena, Gravina, Antonietta Gerarda, Romano, Marco, Loguercio, Carmelina, Federico, Alessandro, Maiello, Evaristo, Tuccillo, Concetta, Morgillo, Floriana, Troiani, Teresa, Di Maio, Massimo, Martinelli, Erika, and Ciardiello, Fortunato
- Subjects
Cancer Research ,Lung Neoplasms ,gut microbiota ,Rectal Neoplasms ,Antibodies, Monoclonal, Humanized ,NSCLC ,avelumab ,cetuximab ,mCRC ,Circulating Tumor DNA ,Gastrointestinal Microbiome ,Proto-Oncogene Proteins p21(ras) ,Oncology ,Carcinoma, Non-Small-Cell Lung ,RNA, Ribosomal, 16S ,Antineoplastic Combined Chemotherapy Protocols ,Colonic Neoplasms ,Humans ,Colorectal Neoplasms - Abstract
Gut microbiota is involved in immune modulation and immune checkpoint inhibitors (ICIs) efficacy. Single-arm phase II CAVE-mCRC and CAVE-LUNG clinical trials investigated cetuximab + avelumab combination in RAS wild-type (WT) metastatic colorectal cancer (mCRC) and chemo-refractory nonsmall cell lung cancer (NSCLC) patients, respectively. A comprehensive gut microbiota genetic analysis was done in basal fecal samples of 14 patients from CAVE-mCRC trial with circulating tumor DNA (ctDNA) RAS/BRAF WT and microsatellite stable (MSS) disease. Results were validated in a cohort of 10 patients from CAVE-Lung trial. 16S rRNA sequencing revealed 23 027 bacteria species in basal fecal samples of 14 patients from CAVE-mCRC trial. In five long-term responding patients (progression-free survival [PFS], 9-24 months) significant increases in two butyrate-producing bacteria, Agathobacter M104/1 (P=.018) and Blautia SR1/5 (P=.023) were found compared to nine patients with shorter PFS (2-6months). A significantly better PFS was also observed according to the presence or absence of these species in basal fecal samples. For Agathobacter M104/1, median PFS (mPFS) was 13.5months (95% confidence interval [CI], 6.5-20.5months) vs 4.6months (95% CI, 1.8-7.4months); P=.006. For Blautia SR1/5, mPFS was 5.9months (95% CI, 2.2-9.7months) vs 3.6months (95% CI, 3.3-4.0months); P=.021. Similarly, in CAVE-Lung validation cohort, Agathobacter M104/1 and Blautia SR1/5 expression were associated with PFS according to their presence or absence in basal fecal samples. Agathobacter and Blautia species could be potential biomarkers of outcome in mCRC, and NSCLC patients treated with cetuximab + avelumab. These findings deserve further investigation.
- Published
- 2022
85. Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic
- Author
-
Stefania Napolitano, Vincenza Caputo, Anna Ventriglia, Giulia Martini, Carminia Maria Della Corte, Vincenzo De Falco, Stefano Ferretti, Erika Martinelli, Floriana Morgillo, Davide Ciardiello, Ferdinando De Vita, Michele Orditura, Morena Fasano, Fortunato Ciardiello, Teresa Troiani, Napolitano, Stefania, Caputo, Vincenza, Ventriglia, Anna, Martini, Giulia, Della Corte, Carminia Maria, De Falco, Vincenzo, Ferretti, Stefano, Martinelli, Erika, Morgillo, Floriana, Ciardiello, Davide, De Vita, Ferdinando, Orditura, Michele, Fasano, Morena, Ciardiello, Fortunato, and Troiani, Teresa
- Subjects
Cancer Research ,Oncology ,Neoplasms ,Liquid Biopsy ,COVID-19 ,Humans ,Precision Medicine ,Pandemics - Abstract
CoronaVirus disease-2019 has changed the delivery of health care worldwide and the pandemic has challenged oncologists to reorganize cancer care. Recently, progress has been made in the field of precision medicine to provide to patients with cancer the best therapeutic choice for their individual needs. In this context, the Foundation Medicine (FMI)-Liquid@Home project has emerged as a key weapon to deal with the new pandemic situation. FoundationOne Liquid Assay (F1L) is a next-generation sequences-based liquid biopsy service, able to detect 324 molecular alterations and genomic signatures, from May 2020 available at patients’ home (FMI-Liquid@Home). We analyzed time and costs saving for patients with cancer, their caregivers and National Healthcare System (NHS) with FMI-Liquid@Home versus F1L performed at our Department. Different variables have been evaluated. Between May 2020 and August 2021, 218 FMI-Liquid@Home were performed for patients with cancer in Italy. Among these, our Department performed 153 FMI-Liquid@Home with the success rate of 98% (vs. 95% for F1L in the hospital). Time saving for patients and their caregivers was 494.86 and 427.36 hours, respectively, and costs saving was 13 548.70€. Moreover, for working people these savings were 1084.71 hours and 31 239.65€, respectively. In addition, the total gain for the hospital was 163.5 hours and 6785€, whereas for NHS was 1084.71 hours and 51 573.60€, respectively. FMI-Liquid@Home service appears to be useful and convenient allowing time and costs saving for patients, caregivers, and NHS. Born during the COVID-19 pandemic, it could be integrated in oncological daily routine in the future. Therefore, additional studies are needed to better understand the overall gain and how to integrate this service in different countries.
- Published
- 2022
86. Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies
- Author
-
Scott Kopetz, Christine Megerdichian Parseghian, Jonathan M. Loree, Stefania Napolitano, Parseghian, C. M., Napolitano, S., Loree, J. M., and Kopetz, S.
- Subjects
0301 basic medicine ,Cancer Research ,Colorectal cancer ,Protein Kinase Inhibitor ,Drug resistance ,medicine.disease_cause ,Article ,03 medical and health sciences ,Paracrine signalling ,0302 clinical medicine ,Acquired resistance ,Neoplasms ,Biomarkers, Tumor ,medicine ,Humans ,PTEN ,Molecular Targeted Therapy ,ErbB Receptor ,Protein Kinase Inhibitors ,Mutation ,biology ,business.industry ,Cancer ,medicine.disease ,ErbB Receptors ,030104 developmental biology ,Oncology ,Ectodomain ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Neoplasm ,business ,Human - Abstract
Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most commonly mutated innate and acquired oncogenes in cancer, there are a number of other mechanisms that limit the effectiveness of EGFRi. Patients with innate resistance have been found to contain BRAFV600E mutations, and possibly MET, MEK, PIK3CA, PTEN, and HER2 alterations. Meanwhile, BRAFV600E mutations may also be involved in acquired resistance to EGFRi, in addition to EGFR ectodomain mutations, MET alterations, and possibly HER2 amplification. In addition, paracrine effects and cell-fate mechanisms of resistance are being increasingly described as contributing to acquired resistance. Utilization of circulating tumor DNA has been paramount in monitoring the dynamic nature of acquired resistance and has helped to guide treatment decisions, particularly in the EGFRi rechallenge setting. Herein, we provide an in-depth review of EGFRi-resistance mechanisms and describe the current therapeutic landscape in the hopes of identifying effective rechallenge strategies.
- Published
- 2019
87. Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data
- Author
-
Emilia Sardo, Stefania Napolitano, Carminia Maria Della Corte, Davide Ciardiello, Antonio Raucci, Gianluca Arrichiello, Teresa Troiani, Fortunato Ciardiello, Erika Martinelli, Giulia Martini, Sardo, E., Napolitano, S., Corte, C. M. D., Ciardiello, D., Raucci, A., Arrichiello, G., Troiani, T., Ciardiello, F., Martinelli, E., and Martini, G.
- Subjects
Multiparametric approach ,Medicine (miscellaneous) ,Omics ,Biomarker ,Colorectal cancer - Abstract
Colorectal cancer (CRC) is one of the most frequent tumours and one of the major causes of morbidity and mortality globally. Its incidence has increased in recent years and could be linked to unhealthy dietary habits combined with environmental and hereditary factors, which can lead to genetic and epigenetic changes and induce tumour development. The model of CRC progression has always been based on a genomic, parametric, static and complex approach involving oncogenes and tumour suppressor genes. Recent advances in omics sciences have sought a paradigm shift to a multiparametric, immunological-stromal, and dynamic approach for a better understanding of carcinogenesis and tumour heterogeneity. In the present paper, we review the most important preclinical and clinical data and present recent discoveries in the field of transcriptomics, proteomics, metagenomics and radiomics in CRC disease.
- Published
- 2021
88. Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
- Author
-
Erika Martinelli, Teresa Troiani, Lucia Esposito, Nicola Normanno, Davide Ciardiello, Carmine Pinto, Evaristo Maiello, Chiara Cremolini, Tiziana Latiano, Vincenzo Famiglietti, Giuseppe Santabarbara, Giulia Martini, Antonio Avallone, Stefania Napolitano, Fortunato Ciardiello, Filippo Pietrantonio, Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T., Maiello, E., Pietrantonio, F., Cremolini, C., Santabarbara, G., Pinto, C., Troiani, T., Martinelli, E., Ciardiello, F., and Martini, G.
- Subjects
Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Gastroenterology ,Article ,Refractory ,Statistical significance ,Internal medicine ,Medicine ,RC254-282 ,Chemotherapy ,Univariate analysis ,Cetuximab ,business.industry ,Hazard ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,skin toxicity ,Rechallenge anti‐EGFR ,Oncology ,mCRC ,rechallenge anti-EGFR ,Biomarker (medicine) ,Immunotherapy ,MCRC ,Skin toxicity ,immunotherapy ,business ,medicine.drug - Abstract
The single-arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first-line anti-EGFR-based chemotherapy, who progressed and received a subsequent line of therapy. The correlation of skin toxicity (ST) and different clinico-molecular variables with overall survival (OS), progression-free survival (PFS) and response rate (RR) was assessed at univariate and multivariate analysis. A total of 33/77 (42.9%) patients experienced grade 2–3 ST and displayed median OS (mOS) of 17.8 months (CI 95%, 14.9–20.6), whereas 44/77 (57.1%) patients with grade 0–1 ST exhibited mOS of 8.2 months (CI 95%, 5.5–10.9), (hazard ratio (HR), 0.51, CI 95%, 0.29–0.89, p = 0.019). Median PFS (mPFS) was 4.6 months (CI 95%, 3.4–5.7) in patients with grade 2–3 ST, compared to patients with grade 0–1 ST with mPFS of 3.4 months (CI 95%, 2.7–4.1, HR, 0.49, CI 95%, 0.3–0.8, p = 0.004). Grade 2–3 ST (HR, 0.51, p = 0.019) and RAS/BRAF/EGFR WT circulating tumor DNA (ctDNA) (HR, 0.50, CI 95%, 0.27–0.9, p = 0.019) had a statistically significant effect on OS at univariate analysis. At the multivariate analysis, RAS/BRAF/EGFR WT ctDNA status maintained statistical significance (HR, 0.49, p = 0.023), whereas there was a trend towards ST grade 2–3 (HR, 0.54, CI 95%, 0.29–1.01, p = 0.054). Skin toxicity is a promising biomarker to identify patients with mCRC that could benefit of anti-EGFR rechallenge.
- Published
- 2021
89. How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma
- Author
-
Stefania Napolitano, Francesco Selvaggi, Maria Stanzione, Fortunato Ciardiello, Fabrizio Urraro, Erika Martinelli, Alessandro Federico, Giulia Martini, Carminia Maria Della Corte, Valeria Nacca, M. Niosi, Davide Ciardiello, Walter Santaniello, Fernando Paragliola, Marcello Dallio, Martini, G., Ciardiello, D., Paragliola, F., Nacca, V., Santaniello, W., Urraro, F., Stanzione, M., Niosi, M., Dallio, M., Federico, A., Selvaggi, F., Corte, C. M. D., Napolitano, S., Ciardiello, F., and Martinelli, E.
- Subjects
Sorafenib ,Oncology ,Cancer Research ,medicine.medical_specialty ,AFP ,multimodal treatment ,Ipilimumab ,Immune checkpoint inhibitor ,Pembrolizumab ,Review ,Ramucirumab ,immune checkpoint inhibitors ,chemistry.chemical_compound ,Atezolizumab ,Internal medicine ,Medicine ,HCC ,RC254-282 ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,biomarkers ,Biomarker ,digestive system diseases ,chemistry ,Liver function ,Nivolumab ,business ,Lenvatinib ,medicine.drug - Abstract
Simple Summary HCC is a very aggressive disease and patients diagnosed in an advanced/metastatic setting obtain poor survival outcomes with standard treatments. In recent years, the introduction of immunotherapy strategies, such as immune checkpoint inhibitors as single agents and in combination with already approved local and systemic treatments, has strongly changed the therapeutic landscape of HCC. Soon, the discovery of novel potential immune targets, together with the understanding of potential biomarkers of resistance, will help to better define novel treatment opportunities for patients with HCC. Abstract Hepatocellular carcinoma (HCC) is one of the leading causes of death worldwide. The use of local treatment, such as surgical resection, liver transplant, and local ablation, has improved the survival of patients with HCC detected at an early stage. Until recently, the treatment of patients with metastatic disease was limited to the use of the multikinase inhibitor (MKI) sorafenib with a marginal effect on survival outcome. New target approaches, such as the oral MKI lenvatinib in first-line treatment and regorafenib, ramucirumab, and cabozantinib in later lines of therapy, have demonstrated efficacy in patients with preserved liver function (Child–Pugh class A) and good performance status. On the other hand, the implementation of immune checkpoint inhibitors directed against PD-1 (nivolumab and pembrolizumab), PD-L1 (atezolizumab), and anti-CTLA4 (ipilimumab) in the management of advanced HCC has strongly changed the continuum of care of HCC. Future research should include the evaluation of molecular biomarkers that can help patient selection and provide new insight on potential combined approaches. In this review, we provide an overview of the clinical evidence of the use of immune checkpoint inhibitors in HCC, and discuss how immunotherapy has been implemented into the continuum of HCC care.
- Published
- 2021
90. Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?
- Author
-
Paloma Martín-Martorell, Carminia Maria Della Corte, Renato Franco, Morena Fasano, Salvatore Cappabianca, Giulia Martini, Amelia Insa, Giovanni Vicidomini, Stefania Napolitano, Raimondo Di Liello, Floriana Morgillo, Insa, Amelia, Martín-Martorell, Paloma, Di Liello, Raimondo, Fasano, Morena, Martini, Giulia, Napolitano, Stefania, Vicidomini, Giovanni, Cappabianca, Salvatore, Franco, Renato, Morgillo, Floriana, and Della Corte, Carminia Maria
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Second line therapy ,NSCLC ,Retrospective data ,Second line ,First line therapy ,Cancer immunotherapy ,Retrospective Studie ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Chemotherapy ,Humans ,Retrospective Studies ,Response rate (survey) ,ICI resistance ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Hematology ,Immunotherapy ,Non small cell ,Neoplasm Recurrence, Local ,business ,Human - Abstract
Cancer immunotherapy has produced an unprecedented durable response rate, thus shifting from traditional doublet chemotherapy to immunotherapy-based treatments with and without chemotherapy as the first line strategies for advanced non-small cell lung cancer patients without a molecular driver. However, the majority of patients do not benefit from the treatment or may relapse after a period of response. As few treatment options are available after failure of cancer immunotherapy, including the combination of chemotherapy and anti-angiogenic drugs, a better understanding of the mechanisms limiting cancer immunotherapy may be of help in the definition of the best second line. Whereas only retrospective data support an immunotherapy rechallenge approach, new combination strategies including immunotherapy and cell-signaling inhibitors or double immunotherapy represent the newest and most promising strategy to overcome primary or acquired resistance to first line immunotherapy.
- Published
- 2021
91. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer
- Author
-
Stefania Napolitano, Vincenzo Famiglietti, Vincenzo De Falco, J. Ros, Elena Elez Fernandez, Pietro Paolo Vitiello, Fortunato Ciardiello, Evaristo Maiello, Tiziana Latiano, Teresa Troiani, Giulia Martini, Davide Ciardiello, Erika Martinelli, Institut Català de la Salut, [Ciardiello D] Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80131 Naples, Italy. Oncologia Medica, Ospedale Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy. [Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T] Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80131 Naples, Italy. [Ros J] Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80131 Naples, Italy. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, 08035 Barcelona, Spain. [Elez Fernandez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, 08035 Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Ciardiello, D., Martini, G., Famiglietti, V., Napolitano, S., De Falco, V., Troiani, T., Latiano, T. P., Ros, J., Fernandez, E. E., Vitiello, P. P., Maiello, E., Ciardiello, F., and Martinelli, E.
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,rechallenge ,anti-EGFR monoclonal antibodies ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Review ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES] ,Growth factor receptor ,Metàstasi ,Anti-EGFR monoclonal antibodie ,Internal medicine ,Recte - Càncer - Tractament ,Medicine ,Panitumumab ,Còlon - Càncer -Tractament ,Other subheadings::/therapeutic use [Other subheadings] ,Liquid biopsy ,RC254-282 ,Chemotherapy ,Cetuximab ,business.industry ,Otros calificadores::/uso terapéutico [Otros calificadores] ,metastatic colorectal cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS] ,medicine.disease ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES] ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer cell ,Biomarker (medicine) ,Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS] ,business ,medicine.drug - Abstract
Simple Summary The survival of patients with metastatic colorectal cancer (mCRC) has been improved over the years and now reaches 30–40 months. However, few therapeutic options are available after failure of first- and second-line treatments. In fact, prognosis of chemo-refractory mCRC remains poor. Therefore, new therapeutic strategies are needed. Emerging evidence suggest that retreatment with epidermal growth factor (EGFR) inhibitors after a treatment break, in patients that obtained a clinical benefit by previous anti-EGFR, could lead to prolonged survival. The rationale beyond this “rechallenge” strategy is that after a “treatment holiday” EGFR resistant cancer cells decay, restoring the sensibility to EGFR blockade. In this review we analyze the current knowledge of retreatment with EGFR inhibitors, examine the role of novel biomarkers that can guide the appropriate selection of patients. Finally, we discuss future perspectives and on-going clinical trials. Abstract The prognosis of patients with metastatic colorectal cancer (mCRC) who progressed to the first and the second lines of treatment is poor. Thus, new therapeutic strategies are needed. During the last years, emerging evidence suggests that retreatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MAbs) in the third line of mCRC patients, that have previously obtained clinical benefit by first-line therapy with anti-EGFR MAbs plus chemotherapy, could lead to prolonged survival. The rationale beyond this “rechallenge” strategy is that, after disease progression to first line EGFR-based therapy, a treatment break from anti-EGFR drugs results in RAS mutant cancer cell decay, restoring the sensitivity of cancer cells to cetuximab and panitumumab. In fact, rechallenge treatment with anti-EGFR drugs has shown promising clinical activity, particularly in patients with plasma RAS and BRAF wild type circulating tumor DNA, as defined by liquid biopsy analysis at baseline treatment. The aim of this review is to analyze the current knowledge on rechallenge and to investigate the role of novel biomarkers that can guide the appropriate selection of patients that could benefit from this therapeutic strategy. Finally, we discuss on-going trials and future perspectives.
- Published
- 2021
92. Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer
- Author
-
Stefania Napolitano, Erika Martinelli, Antonietta Gerarda Gravina, Teresa Troiani, Alessandra Perrone, Luigi Pio Guerrera, Pietro Paolo Vitiello, Rossella Napolitano, Gabriella Suarato, Emilio Francesco Giunta, Vincenzo De Falco, Fortunato Ciardiello, Guerrera, L. P., Napolitano, S., De Falco, V., Giunta, E. F., Vitiello, P. P., Gravina, A. G., Suarato, G., Perrone, A., Napolitano, R., Martinelli, E., Ciardiello, F., and Troiani, T.
- Subjects
Colorectal cancer ,Disease ,Causes of cancer ,medicine ,Humans ,Liquid biopsy ,Gene ,Predictive biomarker ,business.industry ,Metastatic colorectal cancer ,Rectal Neoplasms ,Primary and acquired resistance ,Gastroenterology ,Comprehensive genome profiling ,Liquid Biopsy ,medicine.disease ,ErbB Receptors ,Oncology ,Biological significance ,Cancer cell ,Colonic Neoplasms ,Mutation ,Cancer research ,Liquid biosy ,EGFR mutation ,business - Abstract
Clinical Practice Points • Metastatic colorectal cancer is one of the most common causes of cancer death worldwide. • Primary and acquired resistance mechanisms to anti-EGFR treatment are a challenging topic with several clinical implications. • Primary resistance is defined by the presence of activating mutations in BRAF and RAS genes before treatment initiation, while acquired resistance refers to the selection of pre-existing mutant clones or de novo acquisition of mutations under the pressure of anti EGFR treatment. • Testing mutations in RAS and BRAF genes as predictive biomarkers is mandatory. • Liquid biopsy has acquired growing importance and showed to be reliable when compared to tissue NGS. • Liquid biopsy offers a full overview of the genetic landscape of the disease, overcoming spatial and temporal heterogeneity, when compared to tissue biopsy. • Liquid biopsy can be used to capture the changes in biology of cancer cells under the selective pressure of targeted agents over time. • Using complementary techniques allows to increase the diagnostic power and the biological significance of the results.
- Published
- 2021
93. Abstract 3275: Bromodomain and extraterminal (BET) protein inhibition sensitize BRAFV600E colorectal cancer to standard targeted therapies
- Author
-
Hey Min Lee, Stefania Napolitano, Alexy Sorokin, Melanie N. Woods, Saikat Chowdhury, Jumanah Y. Alshenaifi, Anand K. Singh, John Paul Shen, Funda Meric-Bernstam, Kunal Rai, and Scott Kopetz
- Subjects
Cancer Research ,Oncology - Abstract
Background: Standard treatment in BRAFV600E colorectal cancer (CRC) patients has demonstrated an extremely poor prognosis with only little benefits. Interestingly, BRAFV600E CRC has been identified as a subgroup highly epigenetically regulated in its tumorigenesis and maintenance. Our preliminary data demonstrated loss of BET family genes sensitizes BRAFV600E CRC cells to targeted therapies. However, the activity of BET inhibition is unknown in the context of BRAF mutation. Therefore, we investigated the efficacy of BETi combined with standard treatments in BRAFV600E CRC. Methods: CRISPR-based synthetic lethality screen was conducted using RKO, BRAFV600E CRC cell line. Library containing 355 epigenetic genes was introduced and cells were treated with either DMSO, BRAFi (vemurafenib), or BRAFi/EGFRi (cetuximab). Clonal dropouts under control versus BRAFi or BRAFi/EGFRi lead to identifying top candidate genes potentially synthetic lethal with standard treatments. We further compared the response to targeted therapies between individual BET family (BRD2/3/4) knockout and control BRAFV600E CRC cell lines by XTT or clonogenic assays. Furthermore, BRAFV600E CRC PDX models were treated with vehicle, BETi (iBET151), MEKi (binimetinib), or BETi/MEKi doublet. The efficacy of BETi (zen3694) and BRAFi/EGFRi triplet combination is under investigation. Also, we tested a combination of BETi/MEKi or BETi/BRAFi/EGFRi in the BRAFV600E CRC model with acquired resistance to BRAFi/EGFRi. We assessed treatment response by measuring tumors volume changes for 21 days. For BETi/MEKi combination, RNA-seq and RPPA were performed at 7 days to understand the pharmacodynamics of the combination. Results: Our negative selection screen confirmed loss of BRD2, one of the BET family members, sensitizes cells to both targeted treatments (p < 0.05). BRD2 or BRD4 KO CRC cell lines have shown growth inhibition with BRAFi or BRAFi/EGFRi treatments compared to control (p Conclusion: Our data showed combination of BET inhibition improved sensitivity or overcame resistance to standard targeted therapy in BRAFV600E CRC. Overall, our data suggest that combining BETi with MAPK inhibition could be a novel therapeutic solution for BRAFV600E CRC. Citation Format: Hey Min Lee, Stefania Napolitano, Alexy Sorokin, Melanie N. Woods, Saikat Chowdhury, Jumanah Y. Alshenaifi, Anand K. Singh, John Paul Shen, Funda Meric-Bernstam, Kunal Rai, Scott Kopetz. Bromodomain and extraterminal (BET) protein inhibition sensitize BRAFV600E colorectal cancer to standard targeted therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3275.
- Published
- 2022
94. Resistance mechanisms to anti-EGFR therapy in RAS/RAF wildtype colorectal cancer varies by regimen and line of therapy
- Author
-
Christine Megerdichian Parseghian, Ryan Sun, Melanie Nicole Woods, Stefania Napolitano, Jumanah Alshenaifi, Jason Willis, ShaKayla Kentel Nunez, Alexey Sorokin, Preeti Kanikarla Marie, Kanwal Pratap Singh Raghav, Van K. Morris, John Paul Y.C. Shen, Eduardo Vilar Sanchez, Marko Rehn, Agnes Ang, Teresa Troiani, and Scott Kopetz
- Subjects
Cancer Research ,Oncology - Abstract
3554 Background: The conventional theory for the development of treatment resistance to anti-EGFR for metastatic colorectal cancer (mCRC) is the selective growth advantage of pre-existing therapy-resistant subclones with genomic mechanisms such as RAS mutations, leading to treatment resistance and disease progression. However, the impact of cytotoxic chemotherapy in combination with anti-EGFR on the mechanisms of resistance has not been assessed. Methods: We analyzed paired plasma samples from RAS/BRAF/EGFR wild-type mCRC patients enrolled in three large randomized phase 3 trials of anti-EGFR rechallenge in whom paired baseline and time of progression plasma samples had been collected for sequencing of ctDNA on a platform optimized for very low allele frequencies. 569 patients had paired baseline and progression ctDNA samples analyzed, including 147 in the first line study of FOLFOX +/- panitumumab, 91 patients in third line with panitumumab vs best supportive care, and 331 patients in the third line study of cetuximab vs. panitumumab. The mutational signature of the alterations acquired with therapy was evaluated. We also established colon cancer cell lines with resistance to cetuximab, FOLFOX, and SN38, and profiled transcriptional changes. Results: Using serial plasma samples, we demonstrate that patients whose tumors were treated with and responded to anti-EGFR alone were approximately 5-times more likely to develop acquired mutations at progression compared to those treated with an EGFR inhibitor in combination with cytotoxic chemotherapy (46% vs. 9%, respectively; p < 0.001). Consistent with this clinical finding, cell lines with non-genomic acquired resistance to cetuximab were cross-resistant to cytotoxic chemotherapy and vice-versa, with transcriptomic profiles consistent with epithelial to mesenchymal transition. In contrast, common acquired genomic alterations in the MAPK pathway that drive resistance to EGFR monoclonal antibodies do not impact sensitivity to cytotoxic chemotherapy. Further, contrary to the generally accepted hypothesis of clonal expansion of acquired resistance, in our work we demonstrate that baseline resistant subclonal mutations rarely expanded to become clonal at the time of progression (8%), and most remained subclonal (44%) or disappeared (49%). Conclusions: Collectively, this work outlines a model of resistance where non-genomic mechanisms of resistance common to both EGFR inhibitors and cytotoxic chemotherapy predominate in patients treated with EGFR and chemotherapy combinations. With EGFR inhibitor monotherapy, genomic acquired resistance mechanisms predominate, although only rarely through expansion of pre-existing subclones. These findings have important implications for strategies of EGFR-inhibitor rechallenge studies.
- Published
- 2022
95. How we treat locoregional melanoma
- Author
-
Stefania Napolitano, P.A. Ascierto, V. De Falco, C. Trojaniello, and Teresa Troiani
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Skin Neoplasms ,business.industry ,Sentinel Lymph Node Biopsy ,Melanoma ,Standard treatment ,Sentinel lymph node ,Cancer ,medicine.disease ,medicine.anatomical_structure ,Internal medicine ,Cutaneous melanoma ,medicine ,Humans ,Lymph Node Excision ,Skin cancer ,Stage (cooking) ,Neoplasm Recurrence, Local ,business ,Lymph node - Abstract
Cutaneous melanoma is the most lethal form of skin cancer and its incidence has been increasing in the past 30 years. Although this is completely resectable in most cases, thicker melanoma and those with regional lymph-node involvement are at a high risk of relapse. In recent years, the management of locoregional disease has drastically changed. In particular, in the 8th Edition of the American Joint Committee on Cancer (AJCC), subgroup classification of TNM (tumor–node–metastasis) has been modified, with the addition of the IIID stage. Furthermore, in recent randomized trials, completion lymph node dissection in case of sentinel lymph node biopsy positivity has not been shown to offer any improvement in overall survival versus observation. Consequently, radical dissection has been recommended as the standard treatment, but only in patients with palpable nodal metastases. However, the major novelty in the treatment of locally advanced melanoma has been the introduction of drugs, already used for metastatic disease, that have also shown clinical efficacy in the adjuvant setting. In fact, immunotherapies and, in the case of BRAF V600E/K-mutated melanoma, combination treatment of BRAF and MEK inhibitors have improved recurrence-free survival in these patients. In this paper, we will describe the current management of a patient with radically resectable melanoma and discuss the key points in light of the latest scientific evidence.
- Published
- 2021
96. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
- Author
-
Giancarlo Marone, Floriana Morgillo, Carlo G. Tocchetti, Carminia Maria Della Corte, Remo Poto, Gilda Varricchi, Teresa Troiani, Flora Pirozzi, Luigi Formisano, Valentina Mercurio, Alessandra Cuomo, Stefania Napolitano, Roberto Bianco, Maria Rosaria Galdiero, Poto, Remo, Marone, Giancarlo, Pirozzi, Flora, Galdiero, Maria Rosaria, Cuomo, Alessandra, Formisano, Luigi, Bianco, Roberto, Della Corte, Carminia Maria, Morgillo, Floriana, Napolitano, Stefania, Troiani, Teresa, Tocchetti, Carlo G, Mercurio, Valentina, and Varricchi, Gilda
- Subjects
cardiac toxicity ,medicine.drug_class ,animal diseases ,Immune checkpoint inhibitors ,Immune Checkpoint Inhibitor ,chemical and pharmacologic phenomena ,030204 cardiovascular system & hematology ,Monoclonal antibody ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Antineoplastic Agents, Immunological ,Risk Factors ,Neoplasms ,Cardiac toxicity ,medicine ,immune-related adverse event ,Humans ,Pharmacology (medical) ,Immune Checkpoint Inhibitors ,Cancer ,business.industry ,Antibodies, Monoclonal ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Immune checkpoint ,Cardiotoxicity ,030220 oncology & carcinogenesis ,Cancer research ,immune-related adverse events ,bacteria ,Neoplasm ,Immunotherapy ,biological phenomena, cell phenomena, and immunity ,business ,Human - Abstract
Introduction: Cancer immunotherapies with monoclonal antibodies (mAbs) against immune checkpoints (i.e. CTLA-4 and PD-1/PD-L1) have revolutionized antineoplastic treatments. Immune checkpoint inhibitors (ICIs) approved for cancer immunotherapy are mAbs anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab, pembrolizumab, and cemiplimab), and anti-PD-L1 (atezolizumab, avelumab, and durvalumab). Treatment with ICIs can be associated with immune-related adverse events (irAEs), including an increased risk of developing myocarditis. These findings are compatible with the observation that, CTLA-4, PD-1, and PD-L1 pathways play a central role in the modulation of autoimmunity.Areas covered: In this paper, we start from examining the pathogenesis of cardiovascular adverse events from ICIs, and then we focus on risk factors and strategies to prevent and manage this cardiotoxicity.Expert opinion: There is a growing need for a multidisciplinary approach of ICI-associated cardiotoxicity, involving oncologists, cardiologists, and immunologists. Prevention and effective management of ICIs cardiotoxicity starts with an in-depth screening and surveillance strategies of high-risk patients, in order to improve early detection and appropriate management in a personalized approach
- Published
- 2021
97. NMR profiling of Ononis diffusa identifies cytotoxic compounds against cetuximab-resistant colon cancer cell lines
- Author
-
Teresa Troiani, Stefania Napolitano, Brigida D'Abrosca, Nicoletta Potenza, Vittoria Graziani, Monica Scognamiglio, Antonio Fiorentino, Graziani, V., Potenza, N., D'Abrosca, B., Troiani, T., Napolitano, S., Fiorentino, A., and Scognamiglio, M.
- Subjects
Magnetic Resonance Spectroscopy ,Colorectal cancer ,natural products ,Metabolite ,Oxylipin ,Pharmaceutical Science ,Organic chemistry ,Cetuximab ,Colorectal Neoplasm ,Analytical Chemistry ,chemistry.chemical_compound ,0302 clinical medicine ,QD241-441 ,Drug Discovery ,Cytotoxic T cell ,Ononi ,0303 health sciences ,Caco-2 Cell ,Colonic Neoplasm ,Biological activity ,Ononis variegata ,Biochemistry ,Chemistry (miscellaneous) ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Molecular Medicine ,Ononis diffusa ,Growth inhibition ,Colorectal Neoplasms ,Two-dimensional nuclear magnetic resonance spectroscopy ,HT29 Cells ,medicine.drug ,Human ,oxylipins ,Article ,Natural product ,Plant Extract ,03 medical and health sciences ,Species Specificity ,Cell Line, Tumor ,medicine ,Humans ,Physical and Theoretical Chemistry ,030304 developmental biology ,Cell Proliferation ,Cytotoxic activity ,Plant Extracts ,medicine.disease ,HCT116 Cells ,NMR ,HT29 Cell ,chemistry ,Cell culture ,Drug Resistance, Neoplasm ,Drug Design ,HCT116 Cell ,Ononis ,Caco-2 Cells ,Phytotherapy - Abstract
In the search of new natural products to be explored as possible anticancer drugs, two plant species, namely Ononis diffusa and Ononis variegata, were screened against colorectal cancer cell lines. The cytotoxic activity of the crude extracts was tested on a panel of colon cancer cell models including cetuximab-sensitive (Caco-2, GEO, SW48), intrinsic (HT-29 and HCT-116), and acquired (GEO-CR, SW48-CR) cetuximab-resistant cell lines. Ononis diffusa showed remarkable cytotoxic activity, especially on the cetuximab-resistant cell lines. The active extract composition was determined by NMR analysis. Given its complexity, a partial purification was then carried out. The fractions obtained were again tested for their biological activity and their metabolite content was determined by 1D and 2D NMR analysis. The study led to the identification of a fraction enriched in oxylipins that showed a 92% growth inhibition of the HT-29 cell line at a concentration of 50 µg/mL.
- Published
- 2021
98. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
- Author
-
Valentina Belli, Stefania Napolitano, Virginia Tirino, Pietro Paolo Vitiello, Emilio Francesco Giunta, Nunzia Matrone, Carminia Maria Della Corte, Vincenzo Desiderio, Giulia Martini, Claudia Cardone, Davide Ciardiello, Luigi Mele, L. Poliero, Floriana Morgillo, Vincenzo De Falco, Fortunato Ciardiello, Teresa Troiani, Erika Martinelli, Francesco Selvaggi, Gianpaolo Papaccio, Vitiello, P. P., Martini, G., Mele, L., Giunta, E. F., De Falco, V., Ciardiello, D., Belli, V., Cardone, C., Matrone, N., Poliero, L., Tirino, V., Napolitano, S., Della Corte, C., Selvaggi, F., Papaccio, G., Troiani, T., Morgillo, F., Desiderio, V., Ciardiello, F., and Martinelli, E.
- Subjects
0301 basic medicine ,Cancer Research ,Indazoles ,Colorectal cancer ,DNA damage ,medicine.medical_treatment ,Mice, Nude ,DNA damage response ,Irinotecan ,lcsh:RC254-282 ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Piperidines ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Humans ,Homologous recombination ,Clonogenic assay ,PARP inhibitors ,Chemotherapy ,business.industry ,Research ,Synergism ,Drug interaction ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,digestive system diseases ,Oxaliplatin ,030104 developmental biology ,PARP inhibitor ,Oncology ,030220 oncology & carcinogenesis ,Combination treatment ,Mutation ,Chemopotentiation ,Cancer research ,Female ,business ,Colorectal Neoplasms ,medicine.drug - Abstract
Background Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of chemotherapy are desirable. Poly-ADP-Ribose Polymerase inhibitors (PARPi) have shown to increase the activity of DNA damaging chemotherapeutics used in the treatment of CRC, however previous clinical trials failed to validate these results and pointed out dose-limiting toxicities that hamper the use of such combinations in unselected CRC patients. Nevertheless, in these studies little attention was paid to the mutational status of homologous recombination repair (HRR) genes. Methods We tested the combination of the PARPi niraparib with either 5-fluorouracil, oxaliplatin or irinotecan (SN38) in a panel of 12 molecularly annotated CRC cell lines, encompassing the 4 consensus molecular subtypes (CMSs). Synergism was calculated using the Chou-Talalay method for drug interaction. A correlation between synergism and genetic alterations in genes involved in homologous recombination (HR) repair was performed. We used clonogenic assays, mice xenograft models and patient-derived 3D spheroids to validate the results. The induction of DNA damage was studied by immunofluorescence. Results We showed that human CRC cell lines, as well as patient-derived 3D spheroids, harboring pathogenic ATM mutations are significantly vulnerable to PARPi/chemotherapy combination at low doses, regardless of consensus molecular subtypes (CMS) and microsatellite status. The strongest synergism was shown for the combination of niraparib with irinotecan, and the presence of ATM mutations was associated to a delay in the resolution of double strand breaks (DSBs) through HRR and DNA damage persistence. Conclusions This work demonstrates that a numerically relevant subset of CRCs carrying heterozygous ATM mutations may benefit from the combination treatment with low doses of niraparib and irinotecan, suggesting a new potential approach in the treatment of ATM-mutated CRC, that deserves to be prospectively validated in clinical trials.
- Published
- 2021
99. Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data
- Author
-
N. Zanaletti, Teresa Troiani, Michela Milanesio, Elisabetta Fenocchio, Erika Martinelli, Pasquale Lombardi, Davide Ciardiello, Susanna Rosellò, P. Vitale, Stefania Napolitano, Giulia Martini, Andrés Cervantes, Vincenzo De Falco, Fortunato Ciardiello, Vincenzo Famiglietti, Vitale, P., Zanaletti, N., Famiglietti, V., De Falco, V., Cervantes, A., Rosello, S., Fenocchio, E., Milanesio, M., Lombardi, P., Ciardiello, D., Martini, G., Martinelli, E., Ciardiello, F., Troiani, T., and Napolitano, S.
- Subjects
Oncology ,medicine.medical_specialty ,Pyrrolidines ,Real Life Clinical data ,Pyridines ,Colorectal cancer ,Trifluridine ,chemistry.chemical_compound ,Refractory ,Internal medicine ,Regorafenib ,medicine ,Humans ,Uracil ,Retrospective Studies ,business.industry ,Phenylurea Compounds ,Gastroenterology ,Retrospective cohort study ,medicine.disease ,TAS-102 ,Disease control ,Cancer treatment ,Clinical trial ,Drug Combinations ,chemistry ,mCRC ,Cohort ,chemorefractory ,regorafenib ,Colorectal Neoplasms ,business ,Thymine - Abstract
INTRODUCTION: There have been significant developments in colorectal cancer (CRC) research over the last few years, with the introduction of new agents that have been prolonged median overall survival of metastatic colorectal cancer (mCRC). These therapies have improved patient outcomes; however, despite significant progress in strategies for cancer treatment, their use is limited by development of resistant mechanism. Almost 30% of patients with refractory mCRC will remain good candidates for further treatment. Regorafenib and TAS-102 are novel antitumor agents for patients with refractory mCRC. However, it is unclear which patients may derive a survival benefit from these drugs in real-life clinical practice.; METHODS: We performed a retrospective analysis evaluating safety and efficacy of TAS-102 and regorafenib in a cohort of refractory mCRC patients, in 3 different centers between January 1 2018 and May 31 2020, with the aim of assessing the optimal sequence treatment for these 2 drugs.; RESULTS: One hundred and forty mCRC patients were included in the analysis. Of these patients, 64 received regorafenib and 76 received TAS-102 as first treatment. After progression, in the regorafenib 24 (37%) patients switched to secondary treatment with TAS-102, instead, in the TAS-102 group, among 76 patients, 29 (45%) patients switched to secondary treatment with regorafenib. Disease control was achieved in 8 (12.5%) of 64 patients in the regorafenib group and 17 (22.4%) of 76 patients in the TAS-102 group. In terms of efficacy, the PFS and OS were similar in both treatment groups for primary and secondary treatments. AEs reported in this analysis were mostly consistent with the known safety profiles of regorafenib and TAS-102 in previous clinical trials.; CONCLUSION: The present study is the first one to compare the activity of the two agents in a large cohort of chemo-refractory mCRC patients providing more details about the best sequence, to be incorporated in clinical practice. Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
- Published
- 2021
100. Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results
- Author
-
Fortunato Ciardiello, Michele Caraglia, Stefania Napolitano, Annarita Nappi, Gabriella Brancaccio, Vincenzo De Falco, Domenico Salvatore, Monica Dentice, Teresa Troiani, Emilio Francesco Giunta, Giuseppe Argenziano, Renato Franco, Valentina Belli, Davide Ciardiello, Caterina Miro, Troiani, T., Napolitano, S., Brancaccio, G., Belli, V., Nappi, A., Miro, C., Salvatore, D., Dentice, M., Caraglia, M., Franco, R., Giunta, E. F., De Falco, V., Ciardiello, D., Ciardiello, F., Argenziano, G., Troiani, Teresa, Napolitano, Stefania, Brancaccio, Gabriella, Belli, Valentina, Nappi, Annarita, Miro, Caterina, Salvatore, Domenico, Dentice, Monica, Caraglia, Michele, Franco, Renato, Giunta, Emilio Francesco, De Falco, Vincenzo, Ciardiello, Davide, Ciardiello, Fortunato, and Argenziano, Giuseppe
- Subjects
Druggability ,lcsh:Medicine ,Medicine (miscellaneous) ,Case Report ,Imiquimod ,Disease ,medicine.disease_cause ,Hedgehog pathway ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Medicine ,Melanoma ,030304 developmental biology ,0303 health sciences ,Mutation ,business.industry ,lcsh:R ,SMO ,medicine.disease ,030220 oncology & carcinogenesis ,Cutaneous melanoma ,Cancer research ,Skin cancer ,business ,medicine.drug - Abstract
Melanoma is the most lethal form of skin cancer and its incidence is growing worldwide. In the last ten years, the therapeutic scenario of this disease has been revolutionized by the introduction of targeted therapies and immune-checkpoint inhibitors. However, in patients with many lesions and bulky tumors, in which surgery is no longer feasible, there is a need for new treatment options. Here we report, for the first time to our knowledge, a clinical case where a melanoma patient harboring the SMO p.Gln216Arg mutation has been treated with imiquimod, showing a complete and durable response. To better explain this outstanding response to the treatment, we transfected a melanoma cell line (MeWo) with the SMO p.Gln216Arg mutation in order to evaluate its role in response to the imiquimod treatment. Moreover, to better demonstrate that the antitumor activity of imiquimod was due to its role in suppressing the oncogenic SMO signaling pathway, independently of its immune modulating function, an in vivo experiment has been performed. This clinical case opens up a new scenario for the treatment of melanoma patients identifying a new potentially druggable target.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.